You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 21, June 4, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Radiologic Imaging
 •Renal Diseases
 •Acute Renal Failure
 •Angiology
 •Cardiac Diagnostic Tests
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In response to Dr Shen, patients with contrast-induced nephropathy typically experience an acute increase in serum creatinine level after the contrast exposure, and this generally returns to baseline by 7 to 10 days.1 It is possible that volume expansion due to intravenous saline might explain the nonsignificant change in the mean serum creatinine level in the control group. Although we did not measure renal function beyond 7 days, the short half-life of acetylcysteine and its short period of administration are not consistent with the delayed development of nephropathy. Studies on the prophylactic use of acetylcysteine have yielded conflicting results.2-3 This is probably because the incidence of contrast-induced nephropathy is difficult to estimate and is highly dependent on the definition of acute renal failure, as well as on the patient population studied.

Drs Bagshaw and Culleton suggest that it would be more appropriate to study patients with advanced renal . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Albert Yuh-Jer Shen
JAMA. 2003;289(21):2794-2795.
EXTRACT | FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Sean M. Bagshaw and Bruce F. Culleton
JAMA. 2003;289(21):2795.
EXTRACT | FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Domingo C. Balderramo
JAMA. 2003;289(21):2795-2796.
EXTRACT | FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points
Heiner C. Bucher, Gordon H. Guyatt, Deborah J. Cook, Anne Holbrook, Finlay A. McAlister, and for the Evidence-Based Medicine Working Group
JAMA. 1999;282(8):771-778.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.